Damora Therapeutics Inc.
DMRA | NASDAQ
$22.24
-$0.61 (-2.67%)
Sep 22, 2026, 1:59 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 181K | 830K | 490K | 441K | 188K |
Gross Profit | n/a | -181K | -830K | -490K | -441K | -188K |
Operating Income | -210.87M | -16.9M | -36.46M | -61.21M | -52.23M | -33.64M |
Interest Income | 1.17M | 844K | 1.69M | 722K | 156K | n/a |
Pretax Income | -209.79M | -21.4M | -38.35M | -61.62M | -51.75M | -34.84M |
Net Income | -209.84M | -21.44M | -38.35M | -61.62M | -51.75M | -34.84M |
Selling & General & Admin | 9.69M | 10.32M | 11.86M | 12.51M | 13.3M | 8.82M |
Research & Development | 201.19M | 6.4M | 23.77M | 48.21M | 38.49M | 24.63M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 210.87M | 16.72M | 35.63M | 60.72M | 51.79M | 33.45M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 210.87M | 16.9M | 36.46M | 61.21M | 52.23M | 33.64M |
Income Tax Expense | 50K | 41K | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 1.36M | 1.16M | 1.06M | 1.02M | 1.01M | 1.01M |
Shares Outstanding (Diluted) | 1.36M | 1.16M | 1.06M | 1.02M | 1.01M | 1.01M |
EPS (Basic) | -152.99 | -18.53 | -36.08 | -60.63 | -51.22 | -34.48 |
EPS (Diluted) | -152.99 | -18.53 | -36.08 | -60.63 | -51.22 | -34.48 |
EBITDA | -209.76M | -21.22M | -37.52M | -61.13M | -51.31M | -33.45M |
EBIT | -209.79M | -21.4M | -38.35M | -61.62M | -51.75M | -33.64M |
Depreciation & Amortization | 34K | 181K | 830K | 490K | 441K | 188K |
Add to Watchlist
Select watchlists to add or remove DMRA